

GLAXOSMITHKLINE ORD GBP0.25

ISIN: **GB0009252882** WKN: **0925288**

Overview

2022/01/19 17:37:26

Price

1,672.60 GBp

Difference  -1.82% (-31.00)

General attributes

ISIN	GB0009252882
Symbol	GSK
Exchange	London Stock Exchange
Currency	GBp
Sector	Chemical / Pharmaceutical / Health
Security type	Stock
Market cap (m)	93,072 EUR
Benchmark	FTSE 100

Market data

Bid (Bid size)	1,672.60 GBp (1,472)
Ask (Ask size)	1,673.00 GBp (6,451)
Open	1,693.40 GBp
High	1,706.40 GBp
Low	1,666.40 GBp
Close (prev. day)	1,703.60 GBp
VWAP	1,673.180376 GBp
Volume (pcs)	9,531,792
Trading volume	15,948,407,325.00
Number of trades	15,265
Last size	3,794

Futures and Options

Related Futures	39
Related Options	-

PDF Downloads

Company report: GLAXOSMITHKLINE ORD GBP0.25 

5Y



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research

on instrument		on sector	
Date		Headline	Download
2022/01/17		Global Equity Ratings	
2021/12/28		Global Equity Ratings	
2021/12/09		Global Equity Ratings	
2021/12/01		Global Equity Ratings	
2021/11/05		Global Equity Ratings	

Details

2022/01/19 17:37:26

Price

1,672.60 GBp

Difference ▼ -1.82% (-31.00)

General attributes

ISIN	GB0009252882
Symbol	GSK
Exchange	London Stock Exchange
Currency	GBp
Sector	Chemical / Pharmaceutical / Health
Security type	Stock
Market cap (m)	93,072 EUR
Benchmark	FTSE 100

Market data

Bid (Bid size)	1,672.60 GBp (1,472)
Ask (Ask size)	1,673.00 GBp (6,451)
Open	1,693.40 GBp
High	1,706.40 GBp
Low	1,666.40 GBp
Close (prev. day)	1,703.60 GBp
VWAP	1,673.180376 GBp
Volume (pcs)	9,531,792
Trading volume	15,948,407,325.00
Number of trades	15,265
Last size	3,794

Performance and Risk

	6m	1Y	3Y
Perf (%)	+17.85%	+18.15%	+11.20%
Perf (abs.)	+252.40	+256.00	+167.80
Beta	0.60	0.61	0.67
Volatility	15.64	17.32	21.72

5Y



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days Ø volume 5 days (pcs.)	1,669.52 GBp (7,876,276)
Ø price 30 days Ø volume 30 days (pcs.)	1,615.91 GBp (6,022,735)
Ø price 100 days Ø volume 100 days (pcs.)	1,511.98 GBp (6,277,089)
Ø price 250 days Ø volume 250 days (pcs.)	1,418.98 GBp (6,751,839)
YTD High date	1,737.00 GBp (2022/01/17)
YTD Low date	1,578.80 GBp (2022/01/07)
52 Weeks High date	1,737.00 GBp (2022/01/17)
52 Weeks Low date	1,190.80 GBp (2021/02/26)

All listings for GLAXOSMITHKLINE ORD GBP0.25

Exchange	Date	Time	Price	Trading volume (mio.)	Number of trades
Xetra	2022/01/19	17:35	20.35 EUR	2.34	263
Tradegate	2022/01/19	22:26	20.10 EUR	1.75	232
Stuttgart	2022/01/19	18:36	20.15 EUR	0.07	16
SIX Swiss Exchange	2020/04/21	17:36	21.50 CHF	0.00	1
Munich	2022/01/19	08:00	20.35 EUR	0.00	1

	19					
London Stock Exchange	2022/01/19	17:37	1,672.60 GBp	15,948.41		15,265
Hanover	2022/01/19	08:02	20.35 EUR	0.00		1
Hamburg	2022/01/19	15:38	20.30 EUR	0.01		3
Frankfurt	2022/01/19	21:30	20.10 EUR	0.03		11
FINRA other OTC Issues	2022/01/19	16:41	22.5865 USD	0.03		7
Duesseldorf	2022/01/19	19:30	20.00 EUR	0.00		14
Berlin	2022/01/19	11:54	20.25 EUR	0.02		2

Company profile

Company Logo



Contact Details

GLAXOSMITHKLINE PLC

--

980 Great West Road - TW8 9GS Middlesex

Telefon: 44-20-8047-5000

Fax: 44-20-8047-7807

E-mail: -

PDF Downloads

Company report: GLAXOSMITHKLINE ORD GBP0.25 

Company Profile

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immunoinflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Members of Management Board

Emma Walmsley	Chairman of Managing Board
Hal Barron	Member of Executive Committee
Brian McNamara	Member of Executive Committee
David Redfern	Member of Executive Committee
Deborah Waterhouse	Member of Executive Committee
Diana Conrad	Member of Executive Committee
Iain Mackay	Member of Executive Committee
James Ford	Member of Executive Committee
Karenann Terrell	Member of Executive Committee
Luke Miels	Member of Executive Committee
Phil Thomson	Member of Executive Committee
Regis Simard	Member of Executive Committee
Roger Connor	Member of Executive Committee
Sally Jackson	Member of Executive Committee

Board of directors

Jonathan Symonds	Chairman of Supervisory Board
Anne Beal	Member of Supervisory Board
Hal Barron	Member of Supervisory Board
Harry Dietz	Member of Supervisory Board
Jesse Goodman	Member of Supervisory Board
Laurie Glimcher	Member of Supervisory Board
Charles Bancroft	Member of Supervisory Board
Iain Mackay	Member of Supervisory Board
Lynn Elsenhans	Member of Supervisory Board
Manvinder Singh Banga	Member of Supervisory Board
Urs Rohner	Member of Supervisory Board
Vivienne Cox	Member of Supervisory Board